SCHEMBL3923293

SCHEMBL3923293

NS(=O)(=O)c1ccc(Cl)cc1C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.53
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CA9 Q16790 3/20 0.53
CA4 P22748 2/20 0.53
CA6 P23280 2/20 0.53
CA5A P35218 2/20 0.53
CA7 P43166 2/20 0.53
CA14 Q9ULX7 2/20 0.53
CA5B Q9Y2D0 2/20 0.53
RAB9A P51151 2/20 0.50
PKM P14618 1/20 0.50
CNR2 P34972 4/20 0.44
TRPV4 Q9HBA0 1/20 0.42
CCR2 P41597 2/20 0.42
HSD11B1 P28845 1/20 0.41
POLB P06746 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
CA3 P07451 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4781209 0.83 CA1 (0.42) CA12CA1CA2CA9CA4
SCHEMBL2003288 0.83 TRPV4 (0.60) RAB9APKMCNR2TRPV4CCR2
SCHEMBL30161661 0.83 TRPV4 (0.60) RAB9APKMCNR2TRPV4CCR2
SCHEMBL27872317 0.81 RAB9A (0.50) RAB9APKMCNR2TRPV4CCR2
SCHEMBL3208969 0.80 CNR2 (0.69) CA1CA2CA9CA7CNR2
SCHEMBL27921944 0.79 CA12 (0.55) CA12CA1CA2CA9CA4
SCHEMBL9048102 0.79 CA1 (0.55) CA12CA1CA2CA9CA4
SCHEMBL4638383 0.79 CA12 (0.59) CA12CA1CA2CA9CA4
SCHEMBL16261364 0.78 CA1 (0.53) CA12CA1CA2CA9CA4
SCHEMBL1541130 0.78 CA2 (0.53) CA12CA1CA2CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797065-A4 ACYCLIC 1,3-DIAMINES AND USES THEREFOR SMITHKLINE BEECHAM CORP (US) 2009-03-04 EP disclosed
US-20070259965-A1 Acyclic 1,3-Diamine And Uses Therefor SMITHKLINE BEECHAM CORPORATION 2007-11-08 US disclosed
EP-1797065-A2 ACYCLIC 1,3-DIAMINES AND USES THEREFOR SMITHKLINE BEECHAM CORPORATION (US) 2007-06-20 EP disclosed
WO-2006029210-A2 ACYCLIC 1,3-DIAMINES AND USES THEREFOR SMITHKLINE BEECHAM CORPORATION (US) 2006-03-16 WO disclosed
US-4690934-A N-phenylsulfonylisonicotinamide derivatives and their use as fungicides or bactericides NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1987-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259965-A1 Acyclic 1,3-Diamine And Uses Therefor TRPV4, TRPC4, TRPV1 CA12 2024/4885CA1 1113/4885CA2 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.